Genscript Biotech Corporation
1548
Hisse Senetlerindeki Sıralama
#2133
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Hisse Fiyatı
$4.26
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$9.58B
Değişim (1 gün)
5.38%
Değişim (1 yıl)
110.47%
Ülke
HK
Ticaret Genscript Biotech Corporation (1548)
Kategori
Healthcare
Genscript Biotech Corporation (1548) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 14.88%
Genscript Biotech Corporation şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 14.88%'dir. 2023 yılı sonunda şirketin faaliyet marjı 3.12% idi.
Genscript Biotech Corporation için 2013 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 14.88% | 853.85% |
| 2024 | 1.56% | -50.00% |
| 2023 | 3.12% | -104.46% |
| 2022 | -70.02% | -9.52% |
| 2021 | -77.39% | 47.89% |
| 2020 | -52.33% | 8.91% |
| 2019 | -48.05% | -2,274.21% |
| 2018 | 2.21% | -91.48% |
| 2017 | 25.93% | 19.33% |
| 2016 | 21.73% | 72.87% |
| 2015 | 12.57% | 23.72% |
| 2014 | 10.16% | -28.90% |
| 2013 | 14.29% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 38.59% | -97.41% |
US
|
|
| -149.01% | -110.01% |
US
|
|
| 25.57% | -98.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.06% |
NL
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.